Clinical and Economic Analysis of Effectiveness of Everolimus in the Treatment of HR+, HER2- Advanced Breast Cancer in Russia

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2280
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
2020English

Pcn337 - Hr+/Her2− Advanced Breast Cancer Treatment, Disease Progression, and Survival in Argentina, Brazil, Chile, Colombia, and Mexico

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Everolimus-Based Therapy Versus Chemotherapy Among Patients With HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness From a Chart Review Study

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2015English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis

Scientific Reports
Multidisciplinary
2019English

Development and Clinical Effectiveness of Antiandrogens in the Treatment of Advanced Prostate Cancer

Medical Council
2016English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy